4D Molecular Therapeutics (FDMT) News
NASDAQ: FDMTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
10.23-0.49 (-4.57%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FDMT news summary
We found 7 recent headlines mentioning 4D Molecular Therapeutics (FDMT): 0 in the past week and 6 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, FDMT is down 4.57% at $10.23. The most recent story, "4DMT Announces New Employment Inducement Grants", was published by GlobeNewswire on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest 4D Molecular Therapeutics headlines
- 4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted…GlobeNewswire
- 4DMT Advances 4D-150 Toward Key 2027 Readouts; Q3 Net Loss Widens To $78.1 Mln(RTTNews) - 4D Molecular Therapeutics, Inc. (FDMT) reported third-quarter 2026 financial results, highlighting continued investment in its Phase 3 programs for wet age-related macular degeneration…NasdaqFDMT, BF.B
- 4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming MilestonesEMERYVILLE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted…GlobeNewswire
- Zoetis (ZTS) Q3 Earnings and Revenues Top EstimatesZoetis (ZTS) delivered earnings and revenue surprises of +15.89% and +3.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqZTS, FDMT
- 4DMT to Participate in Upcoming Investor ConferencesEMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted…GlobeNewswire
- 4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?4D Molecular Therapeutics (FDMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqFDMT, ZTS
- 4DMT Announces New Employment Inducement GrantsEMERYVILLE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted…GlobeNewswire